Evidence map›Paper›PMID 12975610›Full record

ArticleGlycoconjugate journal

Syndecan-4 as a molecule involved in defense mechanisms.

Kazuhiro Ishiguro, Tetsuhito Kojima, Takashi Muramatsu

Abstract read
PubMed Publisher
In one paragraph

Article in Glycoconjugate journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Shed syndecan-2 inhibits angiogenesis.Journal of cell science · 2014
    Article
  8. Heparan sulfate proteoglycans.Cold Spring Harbor perspectives in biology · 2011
    Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kazuhiro IshiguroDepartment of Biochemistry and Department of Internal Medicine, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan.
Tetsuhito Kojima
Takashi Muramatsu
Nagoya City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Syndecan-4 is a transmembrane heparan sulfate proteoglycan belonging to the syndecan family. Syndecan-4-deficient [(Synd4(-/-)] mice were produced to clarify the in vivo role of syndecan-4. Synd4(-/-) mice were more susceptible to kappa-carrageenan-induced nephropathy, and the placental labyrinth from the deficient embryos exhibited more thrombi than wild-type ones. Importantly, Synd4(-/-) mice were more susceptible to endotoxin shock. Further analysis revealed that the mechanism to suppress excessive production of interleukin-1beta (1L-1beta) by transforming growth factor-beta (TGF-beta) was impaired in the deficient mice. TGF-beta, one of the cytokines involved in the suppression mechanism, bound to heparan sulfate chain of syndecan-4, which was induced in macrophages and the microvasculature after administration of lipopolysaccharide. Therefore, augmentation of TGF-beta function by induced syndecan-4 was suggested as a mechanism of the suppressive action of syndecan-4 against endotoxin shock.

Indexed as

AnimalsFemaleInterleukin-1LipopolysaccharidesMembrane GlycoproteinsMiceMice, KnockoutPregnancyProteoglycansShock, SepticSyndecan-4Transforming Growth Factor betaInterleukin-1LipopolysaccharidesMembrane GlycoproteinsProteoglycansSdc4 protein, mouseSyndecan-4Transforming Growth Factor beta

Identifiers

PMID12975610
OpenAlexW1980989026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.